Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension. 1990

P Lund-Johansen, and P Omvik, and W White, and O Digranes, and B Helland, and O Jordal, and T Stray
Medical Department, Haukeland Hospital, Bergen, Norway.

The long-term haemodynamic responses to amlodipine, a new long-acting calcium antagonist, were studied both at rest and during exercise in 18 patients (mean age 43 years) with essential hypertension. Blood pressure was measured intra-arterially, cardiac output by dye dilution and heart rate by electrocardiogram. After 11 months of treatment with 5-10 mg amlodipine once daily (mean dose 9 mg/day), mean arterial pressure was reduced by 14% sitting at rest. The reduction in blood pressure was associated with a marked reduction in the total peripheral resistance index (TPRI) of 19% (P less than 0.001). Similar responses were seen supine at rest and during 50W, 100W and 150W bicycle exercise. No significant changes were seen in heart rate. There was a slight increase in stroke index, and cardiac index was preserved at rest and during exercise with a slight trend towards an increase. In 10 of the patients, blood pressure was monitored by a portable blood pressure recorder (Accutracker II, Suntech Medical instruments, Raleigh, North Carolina, USA). Blood pressure was well controlled throughout the full 24 h period after one daily dose. In conclusion, amlodipine exerts a clear antihypertensive effect, both at rest and during exercise, through reduction in the TPRI and without a fall in cardiac pump function. No changes in heart rate were seen and there was no tendency for a reduction in the stroke index during 8 min of exercise at 150 W; on the contrary there was a trend towards an increase. The incidence of side-effects was low (ankle oedema in two patients).

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D005260 Female Females
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

P Lund-Johansen, and P Omvik, and W White, and O Digranes, and B Helland, and O Jordal, and T Stray
April 1977, British journal of clinical pharmacology,
P Lund-Johansen, and P Omvik, and W White, and O Digranes, and B Helland, and O Jordal, and T Stray
January 1977, Postgraduate medical journal,
P Lund-Johansen, and P Omvik, and W White, and O Digranes, and B Helland, and O Jordal, and T Stray
January 1980, Postgraduate medical journal,
P Lund-Johansen, and P Omvik, and W White, and O Digranes, and B Helland, and O Jordal, and T Stray
January 1976, Acta medica Scandinavica,
P Lund-Johansen, and P Omvik, and W White, and O Digranes, and B Helland, and O Jordal, and T Stray
September 1979, European journal of clinical pharmacology,
P Lund-Johansen, and P Omvik, and W White, and O Digranes, and B Helland, and O Jordal, and T Stray
January 1979, Journal of cardiovascular pharmacology,
P Lund-Johansen, and P Omvik, and W White, and O Digranes, and B Helland, and O Jordal, and T Stray
January 1974, Acta medica Scandinavica,
P Lund-Johansen, and P Omvik, and W White, and O Digranes, and B Helland, and O Jordal, and T Stray
November 1975, Postgraduate medicine,
P Lund-Johansen, and P Omvik, and W White, and O Digranes, and B Helland, and O Jordal, and T Stray
January 1974, Acta medica Scandinavica,
P Lund-Johansen, and P Omvik, and W White, and O Digranes, and B Helland, and O Jordal, and T Stray
January 1984, Acta medica Scandinavica. Supplementum,
Copied contents to your clipboard!